Drug Profile

LCB 91

Alternative Names: LCB-91

Latest Information Update: 08 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Iksuda Therapeutics
Developer Iksuda Therapeutics; LigaChem Biosciences
Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer

Highest Development Phases

Research Haematological malignancies; Solid tumours

Most Recent Events

22 Jun 2021 Early research in Haematological malignancies in United Kingdom, South Korea (Parenteral)
22 Jun 2021 Early research in Solid tumours in United Kingdom (Parenteral)
01 Jun 2020 Early research in Solid tumours in South Korea (Parenteral) before June 2020 (LegoChem Biosciences pipeline, June 2020)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com